Vanda Q3 Revenue Jumps 24% to $69.8M, Loss Narrows to $22.6M, 2026 Revenue Guided Above $240M
VNDA sits 16% above its 52-week low of $3.79 on elevated volume (1.9× avg).
Summary
Vanda's Q3 revenue rose 24% to $69.8 million and the loss narrowed to $22.6 million as expenses fell 18% from Q2. Cash stands at $140.5 million, and management guided 2026 revenue above $240 million.
Key Events · Earnings and Guidance · VNDA
-
Q3 Revenue Grows 24% to $69.8M
Total net product sales were $69.8 million versus $56.3 million in Q3 2025 and $50.5 million in Q2 2026; Fanapt contributed $38.8 million and HETLIOZ $21.7 million.
-
Loss Narrows as Expenses Fall 18%
Operating expenses dropped to $93.3 million from $114.3 million in Q2 2026, cutting the net loss to $22.6 million ($0.37 per share) from $62.5 million ($1.04) in Q2.
-
Cash Falls to $140.5M
Cash, equivalents and marketable securities were $140.5 million at September 30, 2026, down $29.5 million in the quarter and $123.4 million from December 31, 2025.
-
2026 Revenue Guidance Above $240M
Management expects full-year 2026 total revenue of greater than $240 million, against $172.1 million booked in the first nine months.
Analysis · VNDA · Life Sciences
The commercial turnaround is taking hold: revenue rose 24% year-over-year to $69.8 million and 38% from Q2, while operating expenses fell 18% to $93.3 million as late-stage trial and launch-prep spending wound down. The quarterly loss narrowed to $22.6 million from $62.5 million in Q2. Cash fell $29.5 million in the quarter to $140.5 million, down $123.4 million since December 31, 2025 — roughly two years of runway at the current burn if expense cuts hold. Management guided full-year 2026 revenue above $240 million, with the BYSANTI launch in Q4 and the Quimilza BLA PDUFA date on December 12, 2026 as the next binary events.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 30.7% of the 1698 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VNDA was trading at $4.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $241.9M. The 52-week trading range was $3.79 to $9.94. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.